Cerenome is trading 6.7% higher at $1.81 in pre-market on November 2; no new company-specific announcement explaining the move surfaced in the search.
- This compares with the October 30 close of $1.70.
- The Nasdaq Composite is up 0.94% and the S&P 500 is up 0.47% in the supplied context. Nasdaq strength may contribute to sentiment, but does not establish a direct cause.
- Cerenome announced Phase 2 trial enrollment completion on October 29, before this move.